Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab
CA224-020
Phase 2 small_molecule active
Quick answer
Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab for Neoplasms by site is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Neoplasms by site
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active